Clinical Rheumatology

, Volume 26, Issue 7, pp 1148–1150 | Cite as

Durable remission of HIV-negative, Kaposi’s sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid arthritis treated with methotrexate

  • Samuel A. Jacobs
  • Nicholas Vidnovic
  • Hitendra Patel
  • Lorinda A. Soma
  • Yuan Chang
  • Noah Bass
  • Steven H. Swerdlow
Case Report

Abstract

Multicentric Castleman disease (MCD) is a nonneoplastic lymphoproliferative disorder that has a poor prognosis. Optimal treatment is unknown. There are a few reported cases of MCD and rheumatoid arthritis. In this study, we report a patient with rheumatoid arthritis diagnosed with Kaposi’s sarcoma herpesvirus-(KSHV, human herpesvirus-8) associated MCD that showed expression of viral IL-6. Treatment with methotrexate (MTX) resulted in a complete remission of her disease lasting for 54+ months. Multiple studies have suggested that MCD and rheumatoid arthritis are associated with overexpression of the growth-promoting cytokine interleukin-6 (IL-6), and that MTX downregulates the production of this cytokine in vivo. As such, we suggest that the dramatic improvement in this patient’s disease is due to the immunomodulatory properties of MTX.

Keywords

Castleman disease Interleukin-6 Methotrexate 

References

  1. 1.
    Castleman B, Towne VW (1954) Case records of the Massachusetts General Hospital: case no. 40231. N Engl J Med 250:1001–1005PubMedCrossRefGoogle Scholar
  2. 2.
    Castleman B, Iverson L, Menendez V (1956) Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 9:822–830PubMedCrossRefGoogle Scholar
  3. 3.
    Keller AR, Hochhotzer L, Castleman B (1972) Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670–683PubMedCrossRefGoogle Scholar
  4. 4.
    Frizzra G (1988) Castleman’s disease and related disorders. Semin Diagn Pathol 5:346–364Google Scholar
  5. 5.
    Dupin N, Diss TL, Kellam P et al (2000) HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95:1406–1412PubMedGoogle Scholar
  6. 6.
    Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J et al (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma (see comments). Science 266:1865–1869PubMedCrossRefGoogle Scholar
  7. 7.
    Soulier J, Grollet L, Oskenhendler E, Cacoub P et al (1995) Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 86:126–180Google Scholar
  8. 8.
    Suda T, Katano H, Delso G et al (2001) HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman’s disease. Pathol Int 51:671PubMedCrossRefGoogle Scholar
  9. 9.
    Katano H, Sata T (1999) An attractive relation of human herpesvirus-8 with multicentric Castleman’s disease. Intern Med 38:221–222PubMedGoogle Scholar
  10. 10.
    DeJong R, Baatenburg R, Kluin PM et al (2003) Sustained high levels of serum HHV-8 DNA years before multicentric Castleman’s disease despite full suppression of HIV with highly active antiretroviral therapy. AIDS 17:1407–1408CrossRefGoogle Scholar
  11. 11.
    Hsu SM, Waldron JA, Xie SS, Barlogie B (1993) Expression of interleukin-6 in Castleman’s disease. Hum Pathol 24:833–839PubMedCrossRefGoogle Scholar
  12. 12.
    Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW (1990) Dysregulated interleukin 6 expression produces a syndrome resembling Castleman’s disease in mice. J Clin Invest 86:592PubMedCrossRefGoogle Scholar
  13. 13.
    Dupin N, Fisher C, Kellam P, Ariad S et al (1996) Distribution of human herpesvirus-8 latently infected cells in Kaposi’s sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma. Proc Natl Acad Sci USA 4546–4551Google Scholar
  14. 14.
    Parravicini C, Corbellino M, Paulli M et al (1997) Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman’s disease. Am J Pathol 151:1517–1522PubMedGoogle Scholar
  15. 15.
    Herrada j,Cabanillas,F,Rice L et al (1988) The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 128(8):652–657Google Scholar
  16. 16.
    Marcelin AG, Aaron L, Mateus C et al (2003) Rituximab therapy for HIV-associated Castleman dsease. Blood 102(8):2786–2788PubMedCrossRefGoogle Scholar
  17. 17.
    Corbellino M, Bestetti G, Scalamogna C et al (2001) Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 98:3473–3475PubMedCrossRefGoogle Scholar
  18. 18.
    Jung CP, Emmerich B, Goebel FD, Bogner JR (2004) Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide. Am J Hematol 75:176–177PubMedCrossRefGoogle Scholar
  19. 19.
    Kumari P, Schechter G, Saini N, Benator D (2000) Successful treatment of human immunodeficiency virus related Castleman’s disease with interferon. Clin Infect Dis 31:602PubMedCrossRefGoogle Scholar
  20. 20.
    Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH (2003) A case of multicentric Castleman’s disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. Ann Hematol 82:766–768;203PubMedCrossRefGoogle Scholar
  21. 21.
    Gerards AH, deLathouder S, DeGroot ER et al (2003) Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology 42:1189–1196PubMedCrossRefGoogle Scholar
  22. 22.
    Aggarwal A, Misra R (2003) Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis. Rheumatol Int 23:134–137PubMedGoogle Scholar
  23. 23.
    Nishimoto N, Sasai M, Shima Y et al (2000) Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95(1):56–61PubMedGoogle Scholar
  24. 24.
    Osborne J, Moore PS, Chang Y (1999) KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. Hum Immunol 60(10):921–927PubMedCrossRefGoogle Scholar
  25. 25.
    Curreli F, Cerimele F, Muralindhar S et al (2002) Transcriptional downregulation of ORF50/Rta by methotrexate inhibits the switch of Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8 from latency to lytic reproduction. J Virol 76:5208–5219PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2006

Authors and Affiliations

  • Samuel A. Jacobs
    • 1
    • 2
    • 3
  • Nicholas Vidnovic
    • 1
    • 2
  • Hitendra Patel
    • 1
    • 2
  • Lorinda A. Soma
    • 1
    • 2
  • Yuan Chang
    • 1
    • 2
  • Noah Bass
    • 1
    • 2
  • Steven H. Swerdlow
    • 1
    • 2
  1. 1.University of Pittsburgh Cancer InstitutePittsburghUSA
  2. 2.Department of PathologyUniversity of Pittsburgh School of MedicinePittsburghUSA
  3. 3.University of Pittsburgh Medical CenterPittsburghUSA

Personalised recommendations